Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria

Transplantation

Volumn 63, Issue 6, 1997, Pages 845-848

  Morrissey, P E ^a   Gohh, R ^b   Shaffer, D ^a   Crosson, A ^a   Madras, P N ^a   Sahyoun, A I ^a   Monaco, A P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; OKT 3; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTILYMPHOCYTE SERUM; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; PANCREAS TRANSPLANTATION; SURVIVAL RATE; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030950099     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199703270-00009     Document Type: Article

References (10)

1. Jordan ML, Shapiro R, Vivas CA, et al. FK506 rescue for resistant rejection of renal allografts under primary CsA immunosuppression. Transplantation 1994; 57: 860.
2. Woodle ES, Perdrizet GA, So S, Jendrisak MD, White HM, Marsh JW. FK506 rescue therapy: early conversion improves efficacy. Transplant Proc 1993; 25: 1990.
3. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 1996; 62: 594.
4. Klintmalm GB, Goldstein R, Gonwa T, et al. Prognostic factors for the successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc 1993; 25: 641.
5. Shaffer D, Simpson MA, Conway P, Madras PN, Monaco AP. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation 1995; 59: 1063.
6. Gruessner RWG, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261.
7. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1996; 61: 1161.
8. Gaber LW, Schroeder TJ, Moore LW, Shakouh-Amiri MH, Gaber AO. The correlation of Banff scoring with reversibility of first and recurrent rejection episodes. Transplantation 1996; 61: 1711.
9. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis or renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
10. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 1384.